Relationship between response rates and median progression-free survival in non-Hodgkin's lymphoma: A meta-analysis of published clinical trials
Author:
Affiliation:
1. Center for Pharmacometrics and Systems Pharmacology; University of Florida; Orlando FL USA
2. Abbvie, Inc.; North Chicago IL USA
3. Merck and Co.; Rahway NJ USA
Funder
AbbVie
Publisher
Wiley
Subject
Cancer Research,Oncology,Hematology,General Medicine
Reference34 articles.
1. Endpoints in cancer clinical trials;Fiteni;J Visc Surg,2014
2. Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology;Sherrill;Onco Targets Ther,2012
3. Evaluation of complete response rate at 30 months (CR30) as a surrogate for progression-free survival (PFS) in first-line follicular lymphoma (FL) studies: results from the prospectively specified follicular lymphoma analysis of surrogacy hypothesis (FLASH) analysis with individual patient data (IPD) of 3,837 patients (pts);Sargent;J Clin Oncol,2015
4. Outcomes and endpoints in trials of cancer treatment: the past, present, and future;Wilson;Lancet Oncol,2015
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Research of Active Compounds from Allii Macrostemonis Bulbus and Potential Targets against Non-Hodgkin’s Lymphoma Based on Network Pharmacology;Current Computer-Aided Drug Design;2024-06
2. Overall and complete response rates as potential surrogates for overall survival in relapsed/refractory multiple myeloma;Future Oncology;2023-04-21
3. Bayesian estimation of two‐part joint models for a longitudinal semicontinuous biomarker and a terminal event with INLA: Interests for cancer clinical trial evaluation;Biometrical Journal;2023-02-27
4. Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera ® ) in combination with CHOP in patients with previously untreated CD20‐positive diffuse large B‐cell lymphoma: A randomized, single‐blind, phase III clinical trial;Hematological Oncology;2022-08-12
5. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial;The Lancet Oncology;2022-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3